ZenaTech Inc (ZENA) is not a strong buy for a beginner, long-term investor at this time. Despite positive news about its drone innovation and a significant YoY revenue increase, the stock's technical indicators, recent price performance, and lack of strong trading signals suggest caution. The stock's bearish trend and lack of recent congress trading or influential insider activity further support a hold recommendation.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. RSI_6 at 27.757 is neutral, and MACD is positively contracting but still weak. Key support levels are at 2.397 and 2.256, with resistance at 2.856 and 2.997. Post-market price is 2.38, up 1.28%, but the regular market saw a significant drop of -9.69%.

ZenaTech's subsidiary is developing cost-effective maritime drones, aligning with Blue UAS requirements for cybersecurity, and advancing quantum navigation systems for GPS-denied environments. Revenue increased by 1225.31% YoY in Q3 2025, showing strong growth potential.
The stock has a bearish technical setup, with a 50% chance of declining further in the next day (-1.02%), week (-3.19%), and month (-4.46%). Insider and hedge fund trading trends are neutral, and there is no recent congress trading data. The company is still unprofitable with a net income of -$12.27M and an EPS of -0.34.
In Q3 2025, ZenaTech's revenue increased to $4.34M, up 1225.31% YoY, and net income improved to -$12.27M, up 1683.55% YoY. EPS rose to -0.34, up 750% YoY. Gross margin remained flat at 100%.
Citi maintains a Buy rating with a $46 price target, citing a potential upside catalyst from the Phase 3 INDIGO readout in early January for ZenaTech's obexlimab drug. This indicates optimism about the company's biotech segment.